A Randomized Evaluation of MoodFX, a Patient-Centred e-Health Tool to Support Outcome Measurement for Depression: Une évaluation randomisée de MoodFX, un outil de santé en ligne centré sur le patient pour soutenir la mesure du résultat dans la dépression.

In terms of response rates (50% or greater improvement from baseline), at 8 weeks the MoodFX response rate for the QIDS-SR was higher than the control group, but narrowly missed statistical significance (4 of 24 [17%] vs. 0 of 25 [0%], respectively, P = 0.050 by Fisher's exact test), whereas at 6 months the MoodFX response rate was significantly higher (7 of 24 [29%] vs. 0 of 25 [0%], P = 0.004).

also in 72 other papers